We observed that blockade of PAK4 kinase activity was sufficient to overcome resistance to anti-PD-1 therapy in B16 melanoma cells as there was a significant reduction in tumor volume in B16 PAK4 KD cells treated with anti-PD-1 compared with those treated with isotype (Fig. 5C). This evidence concerns the gene PAK4 and melanoma.